UK markets close in 7 hours 3 minutes

Arix Bioscience plc (ARIX.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
121.97-0.03 (-0.02%)
As of 09:05AM GMT. Market open.
Full screen
Previous close122.00
Open121.00
Bid121.00 x 0
Ask124.00 x 0
Day's range121.00 - 122.00
52-week range118.00 - 211.40
Volume23,454
Avg. volume157,444
Market cap157.567M
Beta (5Y monthly)1.51
PE ratio (TTM)4.40
EPS (TTM)27.70
Earnings date09 Mar 2022 - 14 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est218.50
  • EQS Group

    Notification of Major Share Holding

    Arix Bioscience PLC (ARIX) 11-Jan-2022 / 17:04 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: ARIX BIOSCIENCE P

  • EQS Group

    Arix Bioscience PLC: Arix Bioscience co-leads $31 million Series A financing for new portfolio company Sorriso Pharmaceuticals

    Arix Bioscience PLC (ARIX) 22-Dec-2021 / 11:05 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. Arix Bioscience co-leads $31 million Series A financing for new portfolio company Sorriso Pharmaceuticals Arix announces a new portfolio company, Sorriso, with a 26% ownership stake Series A proceeds will enable Sorriso Pharmaceuticals to advance its lead programme, a treatment for IBD, into clinical tr

  • EQS Group

    Arix Bioscience PLC: Director/PDMR Shareholdings

    Arix Bioscience PLC17-Dec-2021 / 11:12 GMT/BSTArix Bioscience plcDirector/PDMR ShareholdingsNotification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 1 Details of the person discharging managerial responsibilities / person closely associated a) Name Robert Lyne 2 Reason for the notification a) Position/status CEO and General Counsel b) Initial notification /Amendment Initial Notification 3 Details of the issuer,